181 related articles for article (PubMed ID: 38580335)
1. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
[TBL] [Abstract][Full Text] [Related]
2. PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment.
Johnson S; Karpova Y; Guo D; Ghatak A; Markov DA; Tulin AV
BMC Cancer; 2022 May; 22(1):557. PubMed ID: 35585513
[TBL] [Abstract][Full Text] [Related]
3. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
[TBL] [Abstract][Full Text] [Related]
4. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
[TBL] [Abstract][Full Text] [Related]
5. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
7. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
Gravells P; Grant E; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
[TBL] [Abstract][Full Text] [Related]
8. PARG Inhibitors and Functional PARG Inhibition Models.
Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes.
Karpova Y; Johnson SJ; Bordet G; Guo D; Ghatak A; Markov DA; Tulin AV
Biomed Pharmacother; 2022 Sep; 153():113504. PubMed ID: 36076593
[TBL] [Abstract][Full Text] [Related]
10. Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
Coulson-Gilmer C; Morgan RD; Nelson L; Barnes BM; Tighe A; Wardenaar R; Spierings DCJ; Schlecht H; Burghel GJ; Foijer F; Desai S; McGrail JC; Taylor SS
J Exp Clin Cancer Res; 2021 Oct; 40(1):323. PubMed ID: 34656146
[TBL] [Abstract][Full Text] [Related]
11. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
12. Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase.
Gao H; Coyle DL; Meyer-Ficca ML; Meyer RG; Jacobson EL; Wang ZQ; Jacobson MK
Exp Cell Res; 2007 Mar; 313(5):984-96. PubMed ID: 17276427
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential.
Min W; Wang ZQ
Front Biosci (Landmark Ed); 2009 Jan; 14(5):1619-26. PubMed ID: 19273151
[TBL] [Abstract][Full Text] [Related]
14. Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies.
Chen SH; Yu X
Sci Adv; 2019 Apr; 5(4):eaav4340. PubMed ID: 30989114
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase.
Stowell AI; James DI; Waddell ID; Bennett N; Truman C; Hardern IM; Ogilvie DJ
Anal Biochem; 2016 Jun; 503():58-64. PubMed ID: 27036617
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
Fathers C; Drayton RM; Solovieva S; Bryant HE
Cell Cycle; 2012 Mar; 11(5):990-7. PubMed ID: 22333589
[TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells.
Zhang M; Lai Y; Vasquez JL; James DI; Smith KM; Waddell ID; Ogilvie DJ; Liu Y; Agoulnik IU
Sci Rep; 2020 Mar; 10(1):3836. PubMed ID: 32123273
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
Steffen JD; Coyle DL; Damodaran K; Beroza P; Jacobson MK
J Med Chem; 2011 Aug; 54(15):5403-13. PubMed ID: 21692479
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents.
Matanes E; López-Ozuna VM; Octeau D; Baloch T; Racovitan F; Dhillon AK; Kessous R; Raban O; Kogan L; Salvador S; Lau S; Gotlieb WH; Yasmeen A
Front Oncol; 2021; 11():745981. PubMed ID: 34778062
[TBL] [Abstract][Full Text] [Related]
20. Genomic and biological aspects of resistance to selective poly(ADP-ribose) glycohydrolase inhibitor PDD00017273 in human colorectal cancer cells.
Tsuda K; Kurasaka C; Ogino Y; Sato A
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1709. PubMed ID: 36053937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
